Cpf1 protein, type v gene editing system, and use
By developing Cpf1 protein and V-type CRISPR/Cas12a gene editing system that recognizes multiple PAM sequences, the packaging delivery capacity and targeting range limitation of the existing CRISPR/Cas9 system in gene editing applications has been solved, and the problem of packaging delivery capacity and targeting range limitation in mammals is realized The efficient gene editing of the system has expanded the variety of gene editing tools and provided more options for clinical treatment.
Patent Information
- Application Number
- PCT/CN2023/101562
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-08
- Filing Date
- 2023-06-21
- Publication Date
- 2024-11-14
AI Technical Summary
The existing CRISPR/Cas9 system limits the packaging delivery capacity and targeting range of gene editing due to the large Cas9 protein, and Cas9 recognizes G-rich PAMs, resulting in a limited targeting range in the mammalian genome.
A Cpf1 protein, V-type CRISPR/Cas12a gene editing system was developed. The Cpf1 protein can recognize a variety of different PAM sequences, including PAMs at 3, 2 or even 1 bases, expanding the target range of gene editing. And combines auxiliary proteins and CRISPR array to form a new gene editing system.
This system can achieve gene editing in vitro and in eukaryotic cells, enriches PAM diversity, improves the possibility of accurate editing of specific gene loci, provides more tool choices for clinical treatment, and promotes gene editing in clinical treatment Application.
Smart Images

Figure CN2023101562_14112024_PF_FP_ABST
Abstract
Description
A Cpf1 protein, V-type gene editing system and its application Technical Field
[0001] The present invention relates to the field of genetic engineering technology, and in particular to a Cpf1 protein, a V-type CRISPR / Cas12a gene editing system and applications. Background Art
[0002] The microbial adaptive immune system CRISPR / Cas (Clustered Regularly Interspaced Palindromic Repeats / CRISPR-associated proteins system) helps bacteria and archaea defend against the invasion of foreign nucleic acids. The CRISPR / Cas system contains direct repeat sequences (Direct Repeat, DR), which are separated by unique spacer sequences (Spacer) of foreign DNA. The CRISPR array is transcribed into long transcripts (pre-crRNA, the precursor of CRISPR RNA), which are then processed to produce small mature CRISPR RNA (crRNA), which consists of a spacer sequence and part of the adjacent direct repeat. The crRNA forms a complex with the Cas nuclease and, in some cases, also with the auxiliary Cas protein and serves as a guide for targeting and cutting foreign nucleic acids, thereby achieving interference. DNA recognition by the Cas-crRNA complex requires the presence of a protospacer adjacent motif (PAM, Proto-Spacer Adjacent Motif) near the target site, which helps to distinguish between self and non-self. CRISPR / Cas systems can be roughly divided into two categories based on the number of different proteases: Class I systems use complexes of multiple Cas proteins, such as Cascade, while Class II systems use single effector enzymes, such as Cas9 and Cas12.
[0003] However, in the CRISPR / Cas9 system, because the Cas9 protein is usually large and consists of about 1,300 amino acids, the AAV virus commonly used for in vivo delivery can accommodate a maximum load of 4,500 kb. In addition to accommodating the Cas protein, it also needs to be loaded with other functional elements such as tracrRNA that are indispensable for gene editing. This condition limits the packaging and delivery of most Cas9 proteins, making their application difficult. In addition, Cas9 recognizes G-rich PAM, which makes it impossible to edit some specific target sites, so its targeting range in the mammalian genome is limited. Therefore, it is of great significance to develop new genome editing systems to provide more possibilities for the application of gene editing.
[0004] Summary of the Invention
[0005] The purpose of the present invention is to overcome the shortcomings of the prior art and provide a Cpf1 protein, a V-type CRISPR / Cas12a gene editing system and applications.
[0006] To achieve the above object, the technical solution adopted by the present invention is as follows:
[0007] In a first aspect, the present invention provides a Cpf1 protein, wherein the amino acid sequence of the Cpf1 protein is shown in any one of SEQ ID NOs. 1 to 6.
[0008] The Cpf1 protein of the present invention can recognize a variety of different PAM sequences. It only needs to recognize PAMs with 3 bases, 2 bases, or even 1 base, which can target a wider range, enrich the PAM diversity of existing Cpf1 proteins, and greatly improve the possibility of precise editing of specific gene sites. It provides reference value for further discovering more new Cpf1 nucleases with PAMs rich in C bases, and expands the existing types of gene editing.
[0009] In a second aspect, the present invention provides a nucleic acid encoding the Cpf1 protein, wherein the base sequence of the nucleic acid is shown in any one of SEQ ID NOs. 16 to 21.
[0010] In a third aspect, the present invention provides a V-type CRISPR / Cas12a gene editing system, comprising the Cpf1 protein, auxiliary protein and CRISPR array.
[0011] The gene editing system of the present invention can recognize each unique PAM sequence and can perform gene editing functions in vitro and in eukaryotic cells under the guidance of crRNA, further expanding the types of gene editing tools and enriching the PAM diversity of existing Cpf1 as a gene editing tool, providing more tool options for the use of Cpf1 in clinical treatment, which plays an important role in promoting the application of gene editing in clinical treatment.
[0012] As a preferred embodiment of the V-type CRISPR / Cas12a gene editing system described in the present invention, the CRISPR array includes a direct repeat sequence and a spacer sequence; the direct repeat sequence and the spacer sequence are arranged at intervals.
[0013] Furthermore, the nucleotide sequence of the direct repeat sequence is shown in any one of SEQ ID NOs. 10 to 15.
[0014] As a preferred embodiment of the V-type CRISPR / Cas12a gene editing system described in the present invention, the amino acid sequence of the above-mentioned auxiliary protein is shown in any one of SEQ ID NOs. 7 to 8.
[0015] In a fourth aspect, the present invention applies the V-type CRISPR / Cas12a gene editing system in prokaryotic or eukaryotic gene editing.
[0016] In a fifth aspect, the present invention applies the V-type CRISPR / Cas12a gene editing system in the preparation of biological gene editing preparations.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] (1) Through metagenomic bioinformatics analysis, the present invention has discovered six new V-type CRISPR / Cas12a gene editing systems for the first time and predicted their corresponding direct repeat sequences. The Cpf1 proteins of the six new editing systems can recognize a variety of different PAM sequences, only needing to recognize 3-base, 2-base, or even 1-base PAMs, which can target a wider range and greatly improve the possibility of precise editing of specific gene sites, providing reference value for further discovering more new Cpf1 nucleases with C-rich PAMs.
[0019] (2) The present invention experimentally demonstrates that these six CRISPR / Cas12a gene editing systems can recognize their own unique PAM sequences and can perform gene editing functions in vitro and in eukaryotic cells under the guidance of crRNA. The discovery of the six new gene editing systems in the present invention further expands the types of gene editing tools, enriches the PAM diversity of existing Cpf1 as a gene editing tool, provides more tool options for Cpf1 to be used in clinical treatment, and plays an important role in promoting the application of gene editing in clinical treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 is a schematic diagram of the composition of the CRISPR / Cas12a gene editing system of the present invention, which consists of Cas protein and CRISPR array.
[0021] Figure 2 is a diagram showing the secondary structure predictions of crRNAs in the six CRISPR / Cas12a gene editing systems described in the present invention.
[0022] Figure 3 is a PAM diagram of the six CRISPR / Cas12a gene editing systems described in the present invention.
[0023] Figure 4 is an in vitro cutting experiment diagram of the six CRISPR / Cas12a gene editing systems described in the present invention.
[0024] Figure 5 is a PCR detection diagram of dsODN insertion after gene editing in eukaryotic cells using the six CRISPR / Cas12a gene editing systems described in the present invention. DETAILED DESCRIPTION
[0025] To better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. Those skilled in the art should understand that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0026] In the present invention, the Cas12a is also called Cpf1, which is classified into CRISPR system type 2 type V based on homology. The effector protein Cpf1 can be used for genome editing through complementarity with guide RNA. Compared with Cas9, the target DNA recognition and cleavage mechanisms between Cas9 and Cpf1 are different. Cpf1 has the following characteristics: (1) Cpf1 is guided by a single crRNA, while Cas9 uses crRNA and a second small RNA, namely, transactivating crRNA (tracrRNA); (2) Cpf1 recognizes T-rich PAMs, as opposed to G-rich PAMs favored by Cas9; (3) Cpf1 produces staggered ends at the PAM-distal target site, while Cas9 produces blunt ends at the PAM-proximal target site. In comparison, the sticky ends after Cpf1 cleavage are more susceptible to homologous recombination repair; (4) Cpf1 contains a RuvC domain but lacks a detectable second nuclease domain, while Cas9 uses HNH and RuvC nuclease domains to cleave the target DNA chain and non-target DNA chain, respectively.
[0027] Unless otherwise specified, the experimental methods used in the examples are conventional methods; the materials, reagents, etc. used are all available from commercial sources unless otherwise specified.
[0028] Example 1: Six V-type CRISPR / Cas12a gene editing systems
[0029] In this example, CRISPRCas Finder software was used for metagenomic annotation, and bioinformatics methods such as NUPACK software were used to predict crRNA structure to analyze, predict, and screen the V-type CRISPR / Cas12a system-related proteins and their components to obtain the novel editing system described in the present invention, as shown in Figure 1. The gene editing system of the present invention d is composed of the following multiple components: genetically encoded nuclease Cpf1, auxiliary proteins Cas1, Cas2, Cas4, and CRISPR array. The present invention discovered six new Cpf1 proteins, named as 28c2, 28c6, 28c12, 28c13, 28c15 and 30c9. The 28c2 protein encodes 1262 amino acids, and its sequence is shown in SEQ ID NO.1; the 28c6 protein encodes 1253 amino acids, and its sequence is shown in SEQ ID NO.2; the 28c12 protein encodes 1265 amino acids, and its sequence is shown in SEQ ID NO.3; the 28c13 protein encodes 1274 amino acids, and its sequence is shown in SEQ ID NO.4; the 28c15 protein encodes 1260 amino acids, and its sequence is shown in SEQ ID NO.5; and the 30c9 protein encodes 1251 amino acids, and its sequence is shown in SEQ ID NO.6.
[0030] The auxiliary protein Cas1, whose sequence is shown in SEQ ID NO.7, the auxiliary protein Cas2, whose sequence is shown in SEQ ID NO.8, and the auxiliary protein Cas4, whose sequence is shown in SEQ ID NO.9, are involved in the capture of exogenous genes and the maturation of crRNA.
[0031] CRISPR array includes direct repeats and spacer sequences. These two sequences are arranged at intervals, with a spacer sequence sandwiched between the two repeats. The base composition and length of the repeats in the same bacteria are relatively conservative, and there are slight differences between different bacteria. The six novel CRISPR / Cas12a systems described in the present invention correspond to the repeat sequence (Direct Repeats, R sequence) D, as shown in SEQ ID NO.10 to 15. CRISPR array transcribes to form pre-crRNA, and the Spacer of pre-crRNA is a sequence that can be complementary and paired with the target sequence. Subsequently, pre-crRNA forms a mature crRNA with 5' as a repeat sequence and 3' as a spacer sequence after shearing processing. The crRNA is complementary to the target anchor gene and guides the Cpf1 protein to exercise editing function on the target sequence complementary to the spacer sequence.
[0032] The above sequence is as follows:
[0033] SEQ ID NO.1 (28c2 protein sequence):
[0034] SEQ ID NO.2 (28c6 protein sequence):
[0035] SEQ ID NO.3 (28c12 protein sequence):
[0036] SEQ ID NO.4 (28c13 protein sequence):
[0037] SEQ ID NO.5 (28c15 protein sequence):
[0038] SEQ ID NO.6 (30c9 protein sequence):
[0039] SEQ ID NO.7 (cas1 protein sequence):
[0040] SEQ ID NO.8 (cas2 protein sequence):
[0041] SEQ ID NO.9 (cas4 protein sequence):
[0042] SEQ ID NO.10 (28c2 direct repeat sequence):
[0043] GAATTTCTACTGTTGTAGAT;
[0044] SEQ ID NO.11 (28c6 direct repeat sequence):
[0045] AAATTTCTACTTCTGTAGAT;
[0046] SEQ ID NO.12 (28c12 direct repeat sequence):
[0047] TAATTTCTACTATTGTAGAT;
[0048] SEQ ID NO.13 (28c13 direct repeat sequence):
[0049] AATTTCTACTATGTGTAGAT;
[0050] SEQ ID NO.14 (28c15 direct repeat sequence):
[0051] AAATTTCTACTGTTGTAGAT;
[0052] SEQ ID NO.15 (30c9 direct repeat sequence):
[0053] TAATTTCTACTATTGTAGAT.
[0054] Example 2: Predicting the secondary structure of crRNA for target sequence recognition by gene editing system
[0055] This example predicts the secondary structure of the crRNA used by the six V-type CRISPR / Cas12a gene editing systems described in Example 1 to recognize target sequences.
[0056] The specific operations are as follows:
[0057] By using AlphaFold to simulate the interaction of repeat sequences in vitro at 37°C and perform secondary structure prediction, the secondary structure of the mature crRNA was determined. Under the action of the Cpf1 nuclease, the pre-crRNA removes the upstream sequence of the repeat sequence, resulting in a 20nt repeat sequence and a 23nt spacer sequence to form the mature crRNA, which then fuses with the Cpf1 protein to form the crRNA-Cpf1 complex. The crRNA-Cpf1 complex first scans for a suitable PAM and then continues to scan for a DNA sequence that complements the spacer sequence, activating the Cpf1 nuclease activity, as shown in Figure 2.
[0058] Example 3: In vitro PAM depletion experiment
[0059] This example uses an in vitro PAM depletion experiment to explore the PAM sequences required for the Cas nuclease to recognize the spacer sequences of the six V-type CRISPR / Cas12a gene editing systems described in Example 1.
[0060] The specific operations are as follows:
[0061] (1) For the V-type CRISPR / Cas12a gene editing system in Example 1 (6), the nucleotide sequence encoding the Cas protein was inserted into the psumo protein expression vector by homologous recombination, and the correctly sequenced recombinant plasmid was transformed into E. coli Rosseta 2 (full gold, CD811-02) competent cells. After activation, a Kana-resistant (50 μg / mL) culture dish was coated, and a single clone was picked the next day. After a large amount of bacterial culture, the recombinant protein was purified by Ni column affinity chromatography and molecular sieve purification in turn, and then stored at -80°C for use.
[0062] The nucleotide sequences of 28c2, 28c6, 28c12, 28c13, 28c15 and 30c9 are shown in SEQ ID NOs. 16 to 21, respectively.
[0063] (2) Six random bases NNNNNN were added to the 3' end of the library spacer sequence (its sequence is shown in SEQ ID NO.22) (a total of 4096 insertion fragments, N represents A, G, C, T), and the library was constructed onto the backbone vector using the overlap PCR method to obtain a Spacer-PAM hybrid plasmid with 4096 different PAM combinations but the same 5' end spacer sequence. The Gini value of the random base abundance at the six positions detected by second-generation sequencing was less than 0.1, indicating that the random bases at the six positions were relatively evenly distributed.
[0064] (3) Using the repeat sequence of the V-type CRISPR / Cas12a gene editing system described in Example 2 above and the corresponding library spacer sequence, a 5'-T7 promoter + repeat sequence + spacer sequence format-3' was constructed, and crRNA was obtained by in vitro transcription (NEB, E2040S) and RNA purification (NEB, T2040S).
[0065] (4) Take 10 pmol of the purified Cpf1 protein obtained in step (a) and mix it with 10 pmol of crRNA, and incubate at room temperature to obtain a protein-crRNA complex. Then mix it evenly with 200 ng of the Spacer-PAM mixed plasmid and incubate it at 37°C for 30 minutes. The Cpf1 protein recognizes the appropriate PAM in the 4096 mixed PAM combinations and cuts the Spacer complementary to the crRNA; add an appropriate amount of proteinase K and incubate at room temperature for 15 minutes to digest the excess Cpf1 protein, and then inactivate it at 98°C for 10 minutes to inactivate the proteinase K activity.
[0066] (5) On the Spacer-PAM hybrid plasmid, suitable primers were designed at both ends of random bases to perform PCR amplification and purification of the position containing the spacer sequence and PAM combination, and adapters were added to both ends of the product for second-generation sequencing (the adapters used commercial Illumina sequencing adapter primers: Hieff NGS384 Dual Index Primer Kit for No. 12613ES02; I5 primer: TAAGATTA; I7 primer: GAGATTCC). The PAM depletion threshold of the negative control group was used as the reference benchmark. The depletion of six random bases was analyzed using Weblogo 3. The PAM sequence recognized by each Cpf1 protein was obtained by negative screening.
[0067] The PAM analysis results are shown in Figure 3. These six gene editing systems can recognize a variety of different PAM sequences. 28c2, 28c6, 28c12, and 28c15 recognize PAMs with three bases, while 30c9 and 28c13 only need to recognize PAMs with two or even one base. Simpler PAMs appear more frequently in the genome, which means that the new Cpf1 protein of the present invention can target a wider range and greatly increase the possibility of precise editing of specific gene sites.
[0068] In particular, compared to existing Cpf1 proteins, which mostly recognize PAMs rich in T bases, this limits the use of these Cpf1 proteins for some gene sequences with low T base content. The 30c9 protein of the present invention recognizes PAMs rich in C bases and has editing functions both in vitro and under eukaryotic conditions. On the one hand, it enriches the PAM diversity of existing Cpf1 proteins and can serve as an ideal editing tool for some gene sequences with high GC content. On the other hand, the protein sequence and editing properties of the 30c9 nuclease provide reference value for further discovering more new Cpf1 nucleases with PAMs rich in C bases, expanding the existing gene editing categories.
[0069] The above sequence is as follows:
[0070] SEQ ID NO.16 (28c2 gene sequence):
[0071] SEQ ID NO.17 (28c6 gene sequence):
[0072] SEQ ID NO.18 (28c12 gene sequence):
[0073] SEQ ID NO.19 (28c13 gene sequence):
[0074] SEQ ID NO.20 (28c15 gene sequence):
[0075] SEQ ID NO.21 (30c9 gene sequence):
[0076] SEQ ID NO.22 (Library-spacer sequence):
[0077] ATGGCGAATACTTTTAAAGTCAT;
[0078] The primer sequences are:
[0079] library-NGS-F:
[0080] ACACTCTTTCCCTACACGACGCTCTTCCGATCTgtctacaatcggctcgatcga;
[0081] library-NGS-R:
[0082] GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTgcgcagaccaaaacgatctc.
[0083] Example 4: In vitro cleavage experiment
[0084] This example verifies that the six V-type CRISPR / Cas12a gene editing systems of Example 1 of the present invention have cleavage capabilities in vitro through in vitro cleavage experiments, and verifies the correctness of the PAM identified in Example 3 of the present invention.
[0085] The specific operations are as follows:
[0086] (1) According to the PAM results identified in Example 3 above, a suitable target site was found on the CDKN2A gene, and a DNA fragment with the same target sequence but different PAM was obtained by annealing reaction. Primers were designed on both sides of the site to obtain a DNA fragment with a length of 2000 bp. The target sequences selected by the six CRISPR / Cas12a systems described in the present invention and the PAM sequences to be tested are described in Table 1.
[0087] Table 1. In vitro cleavage target sequences and PAM sequences
[0088] (2) Using the repeat sequence of the V-type CRISPR / Cas12a gene editing system described in Example 1 above, crRNA containing the repeat sequence and the CDKN target site was obtained by in vitro transcription; the purified Cpf1 protein described in Example 3 was incubated with crRNA to form a complex, and then incubated with the CDKN2A-DNA fragment at 37°C for 30 minutes, and then an appropriate amount of proteinase K was added, incubated at room temperature for 15 minutes, and then inactivated at 98°C for 10 minutes; the in vitro cleavage results were detected by 1.5% agarose gel.
[0089] The test results are shown in Figure 4. The results show that the six CRISPR / Cas12a gene editing systems of the present invention all have good cleavage capabilities in vitro, and can cut a 2000bp CDKN2A-DNA fragment into two fragments of 500bp and 1500bp in length, respectively. This shows that the expressed and purified Cpf1 protein is biologically active; these six Cpf1 proteins can recognize targets complementary to the spacer sequence under the guidance of crRNA and perform correct cleavage.
[0090] Example 5: dsODN insertion experiment
[0091] This example verifies the editing ability of the six V-type CRISPR / Cas12a gene editing systems of Example 1 of the present invention in targeting target genes in mammalian eukaryotic cells through dsODN insertion experiments.
[0092] The specific operations are as follows:
[0093] (1) The six Cpf1 proteins described in Example 1 of the present invention were codon-optimized for human origin, and the corresponding nucleotide sequences were cloned into the PX330 eukaryotic expression vector (Addgene, 59909) to obtain the PX330-protein eukaryotic expression plasmid.
[0094] (2) In mammalian cells, taking HEK293T cells as an example, the endogenous CDKN2A gene was selected, and the PAM sequence that can be recognized and cleaved under in vitro conditions identified in Example 3 was used to find a suitable target site. The sequence format was 5'-direct repeat sequence that binds to six Cpf1 proteins-crRNA spacer sequence-3'. It was cloned into the PXZ vector (Addgene, 160229) by the Gibson method, and PXZ-CDKN2A target plasmids with different PAMs targeting different target sites were constructed. The PX330-protein eukaryotic expression plasmid and the PXZ-CDKN2A target plasmid were transfected simultaneously. LtCpf1 was used as the positive control group, and only the PX330-protein eukaryotic expression plasmid was transfected as the negative control. The CDKN2A gene target sites and corresponding PAMs selected in this example are shown in Table 2.
[0095] Table 2. Target sites, PAM sequences, and detection primers used in eukaryotic experiments
[0096] (c) HEK293T cells in good growth condition were co-transfected with PX330-protein eukaryotic plasmid, PXZ-Cpf1 protein-CDKN2A target plasmid, and 1.2 μL dsODN in a 24-well plate. After 72 h, the cells were harvested and DNA was extracted.
[0097] (d) Primers were designed upstream of the CDKN2A gene target site and on the dsODN sequence (see Table 2) for dsODN-PCR amplification. The agarose gel was run to detect the appearance of the target band to determine whether there was dsODN insertion. The insertion of dsODN was detected to verify whether the V-type CRISPR / Cas12a gene editing system of the present invention had editing ability in a eukaryotic cell environment.
[0098] The results of dsODN-PCR electrophoresis are shown in Figure 5. The results show that the PCR bands of corresponding lengths are marked with red triangles, and the six CRISPR / Cas12a gene editing systems in Example 1 all have cutting capabilities in eukaryotic cells.
[0099] In summary, this study, through metagenomic bioinformatics analysis, has unearthed six novel V-type CRISPR / Cas12a gene editing systems and predicted their corresponding direct repeat sequences. The Cpf1 proteins of these six novel editing systems are named: 28c2, 28c6, 28c12, 28c13, 28c15, and 30c9. As a single RNA-guided endonuclease, Cpf1 requires only crRNA for targeting, making it smaller than Cas9 and more convenient for in vivo delivery. The guide RNA design of Cpf1 is simpler and more convenient than that of Cas9. Experimental studies have demonstrated that these six CRISPR / Cas12a gene editing systems can recognize their own unique PAM sequences and, guided by crRNA, can perform gene editing in vitro and in eukaryotic cells. The discovery of these six novel gene editing systems further expands the range of gene editing tools and enriches the existing PAM diversity of Cpf1 as a gene editing tool, providing more tools for its clinical application and playing a significant role in promoting the clinical application of gene editing.
[0100] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that the technical solutions of the present invention may be modified or replaced by equivalents without departing from the essence and scope of the technical solutions of the present invention.
Claims
1. A Cpf1 protein, characterized in that The amino acid sequence of the Cpf1 protein is shown in any one of SEQ ID NOs. 1 to 6.
2. A nucleic acid encoding the Cpf1 protein according to claim 1, characterized in that: The base sequence of the nucleic acid is shown in any one of SEQ ID NOs. 16 to 21.
3. A V-type CRISPR / Cas12a gene editing system, characterized in that: It comprises the Cpf1 protein, auxiliary protein and CRISPR array as claimed in claim 1.
4. The V-type CRISPR / Cas12a gene editing system according to claim 3, characterized in that The CRISPR array includes a direct repeat sequence and a spacer sequence; the direct repeat sequence and the spacer sequence are arranged at an interval.
5. The V-type CRISPR / Cas12a gene editing system according to claim 4, characterized in that The nucleotide sequence of the direct repeat sequence is shown in any one of SEQ ID NOs. 10 to 15.
6. The V-type CRISPR / Cas12a gene editing system according to claim 3, characterized in that The amino acid sequence of the auxiliary protein is shown in any one of SEQ ID NOs. 7 to 8.
7. Use of the type V CRISPR / Cas12a gene editing system according to any one of claims 3 to 6 in gene editing in prokaryotes or eukaryotes.
8. Use of the type V CRISPR / Cas12a gene editing system according to any one of claims 3 to 6 in the preparation of biological gene editing preparations.
Citation Information
Patent Citations
Application of virus-mediated Cpf1 protein in CRISPR / Cpf1 gene editing system
CN106479985A
Cpf1-based plant genome fixed-point editing method
CN108130342A
Genome editing system and method
CN108690845A
Bacillus subtilis polygene editing and expression adjusting and controlling system based on CRISPR Cpf1
CN110951741A
Cpf1 protein and gene editing system
CN113234701A
